Wagner M, Wisniewski A, Bilinska M, Pokryszko-Dragan A, Cyrul M, Kusnierczyk P, Jasek M
Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Weigla 12, 53-114 Wrocław, Poland.
Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Weigla 12, 53-114 Wrocław, Poland.
Hum Immunol. 2014 Aug;75(8):796-801. doi: 10.1016/j.humimm.2014.05.013. Epub 2014 Jun 6.
CD40-CD40L interaction is necessary for the activation of both humoral and cellular immune response and has been suggested to play a role in the pathogenesis of multiple sclerosis (MS). Therefore, we analyzed the combined influence of the CD40 and CD40L variants on MS susceptibility and progression on well-defined Polish population. Our investigation revealed that CT individuals in rs1883832 locus of CD40 possessed almost 1.5-fold higher risk for MS than CC individuals (OR = 1.44; 95%CI = 1.03-2.1; p = 0.032), while this risk for TT individuals was almost 2.5-fold higher (OR = 2.36; 95%CI = 1.19-4.78; p = 0.014). Moreover, for the first time, we observed the association of CD40 gene with MS development and progression. We observed that for the rs1883832CC individuals the age at diagnosis was on average 2 years lower than for the rs1883832CT and rs1883832TT individuals (CI95% = -3.69-(-0.29); p = 0.023). Additionally, we detected that individuals with TT and CT genotypes showed lower risk of developing secondary progressive course in comparison to those with CC genotype. For rs1883832TT individuals this risk was 4-fold lower (HR = 0.24; CI95% = 0.10-0.53; p = 0.00062). Despite the fact that CD40-CD40L pathway plays a key role in development of autoimmune diseases, we were not able to detect gene-gene interactions between CD40 and CD40L polymorphisms associated with multiple sclerosis.
CD40与CD40L的相互作用对于体液免疫和细胞免疫反应的激活都是必需的,并且有人提出其在多发性硬化症(MS)的发病机制中起作用。因此,我们分析了CD40和CD40L基因变体对明确界定的波兰人群中MS易感性和疾病进展的综合影响。我们的研究表明,CD40基因rs1883832位点的CT个体患MS的风险几乎是CC个体的1.5倍(OR = 1.44;95%CI = 1.03 - 2.1;p = 0.032),而TT个体的这一风险几乎高2.5倍(OR = 2.36;95%CI = 1.19 - 4.78;p = 0.014)。此外,我们首次观察到CD40基因与MS的发生和进展相关。我们发现,rs1883832CC个体的诊断年龄平均比rs1883832CT和rs1883832TT个体低2岁(CI95% = -3.69 - (-0.29);p = 0.023)。此外,我们检测到与CC基因型个体相比,TT和CT基因型个体发生继发进展型病程的风险较低。对于rs1883832TT个体,这一风险低4倍(HR = 0.24;CI95% = 0.10 - 0.53;p = 0.00062)。尽管CD40 - CD40L通路在自身免疫性疾病的发展中起关键作用,但我们未能检测到与多发性硬化症相关的CD40和CD40L多态性之间的基因 - 基因相互作用。